Abstract 3516
Background
We discovered that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), which was usually found in nerve cells throughout the brain, was widely shown in mesenchymal non-small cell lung cancers (NSCLC) and their exosomes and was partly responsible for promoting NSCLC invasion and metastasis. However, little is known about the biologic function of UCHL1 and its therapeutic potential in high-grade neuroendocrine lung cancers (HGNEC) including small cell lung cancer (SCLC) and large cell neuroendocrine cancer (LCNEC). Despite a high overall mutation rate in HGNEC, there are currently no molecularly targeted agents with proven clinical benefit for this disease. Here we show preclinical efficacy evoked by targeting UCHL1 that was relevant to prognosis in HGNEC.
Methods
We assessed the protein expressions of UCHL1 in SCLC cell lines (H69, H82, H526) and NSCLC cell lines, additive chemotherapeutic effects by using the combination of cisplatin/etoposide (PE) or cisplatin/irinotecan (PI) with selective UCHL1 inhibitors (WP1130 and LDN57444), whether the immunohistochemical (IHC) expression level of UCHL1 was associated with prognosis and recurrence in HGNEC patients, and the detectability of UCHL1 mRNA by circulating extracellular vesicles (EVs) in lung cancer patients.
Results
UCHL1 was overexpressed in all the SCLC cell lines and mesenchymal NSCLCs but not an epithelial NSCLC cell line. In SCLC model in vitro, combined the target of UCHL1 by selective UCHL1 inhibitors significantly improved the response of PE and PI therapies. IHC analysis of 72 HGNEC patient’s tumor samples (SCLC/ LCNEC = 34/38) demonstrated that UCHL1 expression significantly correlated with unfavorable overall and recurrence-free survival and contributed to distinguishing SCLC from LCNEC. EVs isolated from lung cancer cell lines and the serum from SCLC and adenocarcinoma patient were verified by electron microscopy and nanoparticle tracking analysis. Increased EVs-derived UCHL1 level was shown in the serum from 2 out of 5 SCLC patients with immunohistochemically high UCHL1 expression while no expression was observed in that from 5 adenocarcinoma patients.
Conclusions
UCHL1 can be a potential prognostic marker and a promising druggable target in HGNEC.
Clinical trial identification
Legal entity responsible for the study
Norihiko Ikeda.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract